Sugi Predict

Sugi Predict / Targets / STS

STS

Steryl-sulfatase · P08842 · STS on Sugi Atlas →

80,127 patent compounds predicted against STS, 44,782 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL216601 SCHEMBL216601 0.58 17/20
SCHEMBL216602 SCHEMBL216602 0.58 17/20
SCHEMBL219299 SCHEMBL219299 0.60 16/20
SCHEMBL219521 SCHEMBL219521 0.50 16/20
SCHEMBL219522 SCHEMBL219522 0.50 16/20
SCHEMBL219134 SCHEMBL219134 0.58 15/20
SCHEMBL219135 SCHEMBL219135 0.58 15/20
SCHEMBL217497 SCHEMBL217497 0.56 15/20
SCHEMBL217498 SCHEMBL217498 0.56 15/20
SCHEMBL217415 SCHEMBL217415 0.50 15/20
SCHEMBL217416 SCHEMBL217416 0.50 15/20
SCHEMBL147038 SCHEMBL147038 0.78 14/20
SCHEMBL116666 SCHEMBL116666 0.77 12/20
SCHEMBL217881 SCHEMBL217881 0.50 12/20
SCHEMBL217882 SCHEMBL217882 0.50 12/20
Estrone Sulfuric Acid Estrone Sulfuric Acid (SCHEMBL4616) 0.80 11/20
SCHEMBL223170 SCHEMBL223170 0.80 10/20
SCHEMBL217968 SCHEMBL217968 0.72 10/20
SCHEMBL226425 SCHEMBL226425 0.54 10/20
SCHEMBL217811 SCHEMBL217811 0.53 10/20

Clinical trials — most relevant to STS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy PHASE4COMPLETED
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) PHASE2/PHASE3COMPLETED
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT) PHASE3ACTIVE_NOT_RECRUITING
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment PHASE2/PHASE3COMPLETED
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase PHASE2/PHASE3COMPLETED
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) PHASE3ACTIVE_NOT_RECRUITING
CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients PHASE1/PHASE2COMPLETED
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) PHASE1/PHASE2COMPLETED
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease PHASE2COMPLETED
Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) PHASE1/PHASE2COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® PHASE1/PHASE2COMPLETED
Hormone Replacement Therapy to Treat Turner Syndrome PHASE2COMPLETED
Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults PHASE1COMPLETED
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome PHASE1COMPLETED
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI PHASE1COMPLETED
Chest Wall Deformities in Children - Epidemiological Data nanCOMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Exploring the Role of Neuroactive Steroids in Tourette Syndrome nanUNKNOWN
A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA) nanCOMPLETED
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome) nanCOMPLETED
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) nanCOMPLETED
Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome nanCOMPLETED
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer nanCOMPLETED
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STS binder may also engage these)

ProteinNameSimilarity
Q96EG1 — 0.985 Q96EG1 →
P50426 — 0.983 P50426 →
Q32KH9 — 0.981 Q32KH9 →
Q8BFR4 — 0.981 Q8BFR4 →
Q3TYD4 — 0.979 Q3TYD4 →
Q60HH5 — 0.976 Q60HH5 →
Q32KJ9 — 0.974 Q32KJ9 →
Q5FYA8 — 0.972 Q5FYA8 →
P51690 — 0.971 P51690 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.971 landscape →
P15586 — 0.969 P15586 →
Q1LZH9 — 0.969 Q1LZH9 →
P51689 — 0.967 P51689 →
Q6NRQ1 — 0.967 Q6NRQ1 →
P15589 — 0.966 P15589 →
Q5M900 — 0.964 Q5M900 →
P22304 — 0.964 P22304 →
Q6DYE8 — 0.964 Q6DYE8 →
Q9R1E6 — 0.964 Q9R1E6 →
Q64610 — 0.962 Q64610 →
ENPP2 Autotaxin 0.961 landscape →
Q71RP1 — 0.961 Q71RP1 →
P15396 — 0.961 P15396 →
Q5NDF0 — 0.961 Q5NDF0 →
P33727 — 0.961 P33727 →
Q08890 — 0.961 Q08890 →
A1A4K5 — 0.960 A1A4K5 →
HPSE Heparanase 0.960 landscape →
P15848 — 0.960 P15848 →
Q32KH8 — 0.960 Q32KH8 →